In this activity, experts in NSCLC discuss the latest developments in NSCLC with MET exon 14 skipping alterations. This activity was recorded at the European Society for Medical Oncology (ESMO) Annual Meeting in Barcelona 27 September–1 October 2019.
This activity has been jointly provided by Oakstone and touchIME ONCOLOGY. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians.
After watching this activity, participants should be able to:
This activity has been designed to meet the educational needs of oncologists, nurse specialists, pathologists and other allied healthcare professionals involved in the management of NSCLC.
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relevant commercial interests.
Prof. David Planchard discloses Consultant/Advisory Board positions with AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Eli Lilly, MedImmune, Merck, Novartis, Peer CME, Pfizer, prIME Oncology and Roche.
Prof. Enriqueta Felip has been an advisor or speakers’ bureau member for AbbVie, AstraZeneca, BerGenBio, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Guardant Health, Janssen, Medscape, Merck KGaA, Merck Sharp & Dohme, Novartis, Pfizer, priME Oncology, Roche, Samsung, Takeda and touchIME. She has been an independent Board member of Grifols and has received research funding from Fundación Merck Salud, Grant for Oncology Innovation EMD Serono.
Prof. Frank Griesinger has disclosures from the following companies: Abbvie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, Lilly, Medac, Merck, MSD, Novartis, Pfizer, Roche and Takeda.
Prof. Marina Garassino discloses honoraria from AstraZeneca/MedImmune, Bristol-Myers Squibb, GlaxoSmithKline, MSD Oncology, Roche and Takeda, has performed Consulting or Advisory roles for AstraZeneca, Bristol-Myers Squibb, MSD, Novartis, Roche, Sanofi-Aventis, Takeda and Tiziana Life Sciences, and has been a member of speakers’ bureaux for AstraZeneca, Bristol-Myers Squibb, Celgene, Incyte MSD Oncology, Roche and Takeda; her Institution has received research funding from AstraZeneca/MedImmune, AstraZeneca, Blueprint Medicines, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Incyte, Merck, MSD, Novartis, Pfizer, Roche/Genentech, Spectrum Pharmaceuticals and Takeda.
Prof. Johan Vansteenkiste discloses honoraria/consultation fees from Apotex, AstraZeneca, Boehringer-Ingelheim, Eli Lilly and Roche, and Research grants/support from MSD.
Walter Murray Yarbrough, MD has no financial interests/relationships or affiliations in relation to this activity.
Martin Quinn has no financial interests/relationships or affiliations in relation to this activity.
Oakstone Publishing designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™️. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, participants must review and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
Date of original release: October 22, 2019. Date credits expire: October 22, 2020.
To obtain the CME credit(s), please complete this post-test. To help us assess the impact of the activity and to create further education, please also take a few minutes to complete the evaluation form.
Please complete and then click to see your results to continue.
Please try again
Peripheral oedema is a common adverse event associated with MET inhibitors.1-4
1. Drilon A, et al. Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). J Clin Oncol. 2016;34(suppl):abstract 108
2. Paik PK, et al. Phase II study of tepotinib in NSCLC patients with METex14 mutations. Presentation at 2019 ASCO Annual Meeting; abstract 9005.
3. Wolf J, et al. Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer. (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. Presentation at 2019 ASCO Annual Meeting; abstract 9004.
4. Lu S, et al. Preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. Proceedings: AACR Annual Meeting 2019:abstract CT031.
Please try again
Activation of alternative pathways is a common resistance mechanism to EGFR-TKIs; in particular, amplification of the MET oncogene accounts for 5–20% of acquired resistance causes.
Morgillo F, et al. Mechanisms of resistance to EGFR targeted drugs: lung cancer. ESMO Open 2016;1:e000060.
Please try again
The selective MET inhibitors tepotinib, capmatinib and savolitinib have lower IC50 for MET than the multikinase inhibitor crizotinib.
Rehman S and Dy GK. MET Inhibition in Non-Small Cell Lung Cancer. EMJ Respir. 2018;6:100–111.
Please try again
Both tepotinib and savolitinib have reported that the presence of brain metastases at baseline did not affect the efficacy of these agents in patients with MET exon 14-skipping NSCLC.1,2 Corresponding data have yet to be reported for crizotinib and savolitinib.
1. Paik PK, et al. Phase II study of tepotinib in NSCLC patients with METex14 mutations. Presentation at 2019 ASCO Annual Meeting; abstract 9005.
2. Wolf J, et al. Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer. (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. Presentation at 2019 ASCO Annual Meeting; abstract 9004.